Skip to main content
OpenTrials
Completed

NCT Number: NCT07690501

Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo

This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adipose-derived Stem Cells Excimer Light Stable Vitiligo

Age range

15 year–52 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

Vitiligo is a common disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin.

Adipose tissue-derived stem cells have the capacity to secrete a variable cytokines and growth factors, including hepatocyte growth factor (HGF), interleukin-6 (IL-6), macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGF-β1), tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF), that stimulate angiogenesis, tissue remodeling, and anti-apoptotic processes. Phototherapy has an eminent effect on stoppage of progression and repigmentaion of vitiligo patches. Narrowband ultraviolet B (NB-UVB) and ultraviolet A (UVA), and monochromatic excimer light (MEL) can be used in treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least.
  • Patients who will accept to be enrolled in the study and will sign an informed consent.

Exclusion criteria

  • Unstable vitiligo for more than 6 months.
  • Current bacterial or viral infection in the treatment area.
  • Patients with unrealistic expectation.
  • Very thin patients "poor donor areas".
  • Patients with uncontrolled systemic disease such as diabetes or hypertension.
  • Patients with hepatitis B or C virus infection.
  • Patients with any other skin disease.
  • Patients with bleeding or coagulopathy disorders.
  • Pregnancy and lactation.
  • Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.

Treatment and study plan

Adipose-derived Stem Cells Combined With Excimer Light

Procedure

All patients received adipose-derived stem cells combined with excimer light.

Primary outcomes

  1. Vitiligo Disease Activity (VIDA) Score

    Time frame: 6 months post-procedure

    The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo.

    The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity:

    • 4: Active disease (new lesions or expansion) within the last 6 weeks.
    • 3: Active disease between 6 weeks and 3 months.
    • 2: Active disease between 3 and 6 months.
    • 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer.
    • 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jul 8, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.